Senores Pharma. — 360° view

Senores Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹192 crore and net profit of ₹37 crore for the September 2026 quarter.

Senores Pharma. (NSE: SENORES) closed at ₹1,090.80 on 20 Nov 2026, up 32.1% over the past year. Its market capitalisation is ₹5,024 crore and it trades at 37.6 times earnings.

Share price
₹1,090.80 (20 Nov 2026)
Market cap
₹5,024 Cr (20 Nov 2026)
P/E
37.64 (20 Nov 2026)
Revenue
₹192 Cr (September 2026 quarter)
Net profit
₹37 Cr (September 2026 quarter)
ROCE
15.1% (FY26)
ROE
13.4% (FY26)
Book value
₹218 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,599.00 / ₹706.00 (20 Nov 2026)
1-year return
32.1% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: SENORES

Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.